Psychedelics Research Reform: Federal Policy, Clinical Trials & Access

Executive Summary

Bipartisan lawmakers are moving to permanently codify President Donald Trump's executive order streamlining psychedelics research into federal statute, marking a watershed moment for therapeutic psychedelic medicine in the United States. Representatives Lou Correa (D-CA) and Jack Bergman (R-MI), co-chairs of the Congressional Psychedelics Advancing Therapies (PATH) Caucus, announced in May 2026 their intention to draft legislation that would enshrine the executive order's provisions into permanent law. The move comes as clinical trials for psilocybin, MDMA, and other psychedelic compounds show promising results for treatment-resistant depression, PTSD, and end-of-life anxiety. The executive order, issued earlier in 2026, directed the Drug Enforcement Administration and Food and Drug Administration to reduce bureaucratic barriers that have historically constrained academic and clinical research into Schedule I psychedelics. By converting these directives into statute, Congress would prevent future administrations from reversing the reforms and provide researchers with long-term regulatory certainty. The legislative effort represents the most significant federal psychedelics policy shift since the Controlled Substances Act of 1970 classified these substances as having no accepted medical use.

Why This Matters

The codification effort affects millions of Americans suffering from mental health conditions that have proven resistant to conventional pharmaceutical interventions. According to the National Institute of Mental Health, approximately 21 million U.S. adults experienced at least one major depressive episode in 2020, with roughly one-third showing inadequate response to standard antidepressant medications. The Department of Veterans Affairs estimates that 13 percent of veterans experience PTSD, a condition for which MDMA-assisted therapy has shown 67 percent efficacy in Phase 3 clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies.

The economic implications extend beyond patient care. The global psychedelic therapeutics market was valued at $3.6 billion in 2023 and is projected to reach $10.2 billion by 2028, according to market research firm Grand View Research. Streamlined research pathways would position U.S. biotechnology companies and academic medical centers to capture a larger share of this emerging sector, currently dominated by Canadian and European firms operating under more permissive regulatory frameworks.

For researchers, the legislation would resolve decades of regulatory friction. Since the Controlled Substances Act placed psilocybin, LSD, and MDMA in Schedule I—reserved for substances with high abuse potential and no accepted medical use—scientists have faced extraordinary licensing requirements, limited access to pharmaceutical-grade compounds, and DEA quotas that restrict the total quantity of psychedelics that can be manufactured annually for research purposes. Johns Hopkins University, New York University, and the University of California, San Francisco have all reported multi-year delays in launching psychedelics trials due to these administrative hurdles.

Background and History

The modern psychedelics research reform movement traces its origins to a 1990s renaissance that followed three decades of near-total prohibition.

The First Wave: 1950s-1960s

Between 1950 and 1965, researchers published more than 1,000 clinical papers on psychedelic substances, with pharmaceutical companies including Sandoz and Eli Lilly manufacturing and distributing LSD and psilocybin for psychiatric research. The Central Intelligence Agency conducted Project MKUltra, a covert program testing LSD for interrogation and mind control purposes, while academic psychiatrists explored psychedelics for treating alcoholism, anxiety, and depression. Harvard University psychologists Timothy Leary and Richard Alpert conducted psilocybin studies until their dismissal in 1963 for protocol violations and advocacy that blurred research and recreational use.

Recreational use exploded in the mid-1960s counterculture movement, prompting a political backlash. Congress passed the Drug Abuse Control Amendments of 1965, giving the FDA authority to regulate "dangerous drugs," and California criminalized LSD possession in October 1966. By 1968, possession of LSD was a federal crime.

The Controlled Substances Act and Research Shutdown

The Controlled Substances Act of 1970, codified at 21 U.S.C. § 801 et seq., established five schedules of controlled substances based on abuse potential and medical utility. The DEA placed psilocybin, psilocin, LSD, mescaline, and DMT in Schedule I, defined as substances with "a high potential for abuse," "no currently accepted medical use in treatment in the United States," and "a lack of accepted safety for use under medical supervision." MDMA, initially unscheduled, was emergency-scheduled in 1985 after recreational use as "Ecstasy" became widespread.

Schedule I classification imposed severe research restrictions. Scientists seeking to study these compounds must obtain a DEA Schedule I research registration, secure institutional review board approval, maintain elaborate storage and record-keeping systems, and source compounds from the National Institute on Drug Abuse, which until 2021 held a monopoly on supplying cannabis and psychedelics for federally funded research. The DEA sets annual aggregate production quotas for each Schedule I substance, often limiting the total quantity available for all U.S. researchers combined to mere grams.

Between 1970 and 1990, psychedelics research in the United States effectively ceased. The few studies that proceeded focused on abuse liability rather than therapeutic potential.

The Research Renaissance: 1990-2020

In 1990, psychiatrist Rick Strassman received FDA approval to administer DMT to human volunteers at the University of New Mexico, the first new psychedelics research authorization in two decades. His work, published in 1994, demonstrated that rigorous psychedelics research could meet modern safety and ethical standards.

The Multidisciplinary Association for Psychedelic Studies, founded in 1986 by Rick Doblin, began funding FDA-approved clinical trials of MDMA for PTSD in 2000. The Heffter Research Institute, established in 1993, sponsored psilocybin studies at Johns Hopkins University and other academic medical centers. In 2006, Johns Hopkins researchers published the first controlled psilocybin study in four decades, demonstrating that a single high dose produced mystical experiences with lasting positive effects in healthy volunteers.

The FDA granted MDMA "Breakthrough Therapy" designation for PTSD treatment in 2017, followed by psilocybin for treatment-resistant depression in 2018 and major depressive disorder in 2019. These designations, created under the FDA Safety and Innovation Act of 2012, expedite development and review of drugs treating serious conditions where preliminary evidence suggests substantial improvement over existing therapies.

Oregon became the first state to legalize psilocybin-assisted therapy through Measure 109 in November 2020, establishing a regulatory framework for licensed facilitators to administer psilocybin in supervised settings. Colorado followed with Proposition 122 in November 2022, creating a similar program and decriminalizing possession of psilocybin, psilocin, DMT, ibogaine, and mescaline for adults 21 and older.

Federal Policy Shifts: 2021-2026

The DEA announced in May 2021 that it would register additional manufacturers to produce psilocybin and other Schedule I psychedelics for research, ending NIDA's decades-long monopoly. The agency granted registrations to at least four private manufacturers by 2023, increasing the available supply of pharmaceutical-grade compounds.

In December 2022, the National Defense Authorization Act for fiscal year 2023 included language directing the Department of Defense to study psychedelic treatments for service members with traumatic brain injury and PTSD. The provision, championed by Representatives Dan Crenshaw (R-TX) and Alexandria Ocasio-Cortez (D-NY), allocated $10 million for clinical trials at military medical facilities.

The Congressional Psychedelics Advancing Therapies Caucus launched in January 2024 with Correa and Bergman as co-chairs. The bipartisan group grew to 22 members by 2026, including Representatives Nancy Mace (R-SC), Earl Blumenauer (D-OR), and Morgan Griffith (R-VA).

President Trump issued an executive order on psychedelics research in early 2026, directing federal agencies to streamline licensing, reduce duplicative reviews, and establish clear timelines for research authorization decisions. The order instructed the DEA to process Schedule I research registration applications within 90 days and required the FDA to designate a psychedelics research ombudsman to assist investigators navigating regulatory requirements.

Key Players

Congressional Leadership

Representative Lou Correa represents California's 46th district and serves as Democratic co-chair of the PATH Caucus. A former member of the California State Senate, Correa has emphasized psychedelics research as a veterans' health issue, noting that Orange County has one of the largest veteran populations in California. He introduced the Veterans Psilocybin Training Act in 2023, which would authorize the Department of Veterans Affairs to study psilocybin therapy for veterans with PTSD and depression.

Representative Jack Bergman, a retired Marine Corps lieutenant general representing Michigan's 1st district, serves as Republican co-chair. Bergman has framed psychedelics research as a national security imperative, citing veteran suicide rates and military readiness concerns. According to the VA, an average of 17 veterans died by suicide each day in 2021, a rate 57 percent higher than non-veteran adults after adjusting for age and sex.

Executive Branch Agencies

The Drug Enforcement Administration maintains regulatory authority over controlled substances manufacturing, distribution, and research under 21 U.S.C. § 821-830. DEA Administrator Anne Milgram, appointed in 2021, has overseen the expansion of Schedule I research registrations and increased production quotas for psilocybin from 8 grams in 2020 to 1,500 grams in 2024. The agency's Diversion Control Division processes research registration applications and conducts inspections of facilities storing Schedule I compounds.

The Food and Drug Administration evaluates investigational new drug applications and oversees clinical trials under 21 C.F.R. Part 312. The FDA's Center for Drug Evaluation and Research has granted Breakthrough Therapy designation to multiple psychedelic compounds and established an internal working group on psychedelic drug development in 2023. Commissioner Robert Califf has stated publicly that the agency evaluates psychedelics using the same safety and efficacy standards applied to all investigational drugs.

Research Institutions and Advocacy Organizations

Johns Hopkins Center for Psychedelic and Consciousness Research, established in 2000 as the first such center at a major U.S. medical institution, has published more than 60 peer-reviewed studies on psilocybin. Director Roland Griffiths, who died in 2023, led landmark trials demonstrating psilocybin's efficacy for cancer-related anxiety, major depression, and smoking cessation. The center received a $17 million private donation in 2019 to expand its research program.

The Multidisciplinary Association for Psychedelic Studies has sponsored more than $150 million in psychedelics research since its founding. MAPS completed two Phase 3 trials of MDMA-assisted therapy for PTSD in 2023, enrolling 104 participants across 15 sites. Results showed that 71 percent of participants in the MDMA group no longer met PTSD diagnostic criteria at the two-month follow-up, compared to 48 percent in the placebo group. MAPS submitted a new drug application to the FDA in December 2023; the agency issued a complete response letter in August 2024 requesting additional data on cardiovascular safety and abuse potential, delaying approval.

Usona Institute, a nonprofit medical research organization, has focused exclusively on psilocybin for major depressive disorder. The organization synthesized a proprietary formulation of synthetic psilocybin and received FDA Breakthrough Therapy designation in 2019. Usona completed a Phase 2 trial in 2021 showing significant reduction in depression scores compared to placebo, with effects sustained at one-year follow-up.

Industry and Investment

Compass Pathways, a publicly traded British company, operates the largest psilocybin clinical trial program globally. The company's proprietary formulation, COMP360, is being evaluated in a Phase 3 trial enrolling 960 participants with treatment-resistant depression across North America and Europe. Compass went public on the Nasdaq in September 2020 at a $1.3 billion valuation and has raised more than $350 million in capital.

Atai Life Sciences, a German biopharmaceutical company, has invested in multiple psychedelic drug development programs through subsidiary companies. Atai's portfolio includes companies developing arketamine for depression, ibogaine derivatives for opioid use disorder, and DMT for treatment-resistant depression. The company raised $225 million in a June 2021 initial public offering.

Legal and Regulatory Framework

Federal psychedelics regulation operates under the Controlled Substances Act, which delegates scheduling authority to the Attorney General in consultation with the Secretary of Health and Human Services. The DEA, operating under Department of Justice authority, implements scheduling decisions and enforces the act's provisions.

Schedule I substances face the most restrictive controls. Under 21 U.S.C. § 823(f), researchers must demonstrate that their protocol serves a legitimate research purpose, that the applicant has experience handling controlled substances, and that the research will be conducted in accordance with applicable laws. The DEA conducts background checks, inspects proposed storage facilities, and can deny applications if it determines that registration would be inconsistent with the public interest.

The FDA regulates clinical trials under the investigational new drug framework established in 21 C.F.R. § 312.20. Sponsors must submit preclinical data demonstrating safety in animal models, detailed protocols describing study design and endpoints, and investigator qualifications. For Phase 1 trials, the primary focus is safety and pharmacokinetics; Phase 2 trials evaluate efficacy in small patient populations; Phase 3 trials provide definitive evidence of safety and efficacy in larger populations required for marketing approval.

The FDA's Breakthrough Therapy designation, codified at 21 U.S.C. § 356(a), applies to drugs treating serious conditions where preliminary clinical evidence demonstrates substantial improvement over available therapies. Designation triggers intensive FDA guidance, organizational commitment involving senior managers, and eligibility for rolling review and priority review of the new drug application. The designation does not lower approval standards but accelerates the development timeline through enhanced agency-sponsor collaboration.

State laws create a complex patchwork. Oregon's Measure 109, codified in Oregon Revised Statutes Chapter 475A, established the Oregon Psilocybin Services program, which began accepting facilitator license applications in January 2023 and client sessions in June 2023. The program operates independently of federal law under the state's police powers, though facilitators and clients remain subject to federal prosecution under the Controlled Substances Act—a conflict the Department of Justice has not actively enforced. Colorado's Natural Medicine Health Act, approved by voters in November 2022, created a similar regulatory framework administered by the Department of Regulatory Agencies.

More than 100 U.S. cities and counties have passed resolutions deprioritizing enforcement of laws prohibiting possession of psilocybin and other plant-based psychedelics. These measures, beginning with Denver in May 2019, do not legalize possession but direct local law enforcement to treat psychedelics offenses as lowest priority. Oakland, Santa Cruz, Ann Arbor, Washington D.C., Seattle, and Detroit have adopted similar policies.

Market and Business Implications

Permanent federal research reforms would accelerate the timeline to FDA approval for psychedelic therapeutics, creating a multi-billion-dollar market for pharmaceutical companies, clinics, and ancillary service providers. Investment bank Canaccord Genuity projected in 2023 that the psychedelic therapeutics market could reach $100 billion annually by 2035 if major mental health indications receive regulatory approval.

The business model differs fundamentally from conventional pharmaceuticals. Psychedelic-assisted therapy typically involves a limited number of supervised dosing sessions—often one to three—combined with preparatory and integration psychotherapy, rather than daily medication. MAPS' PTSD protocol, for example, consists of three eight-hour MDMA sessions spaced one month apart, with 12 preparatory and integration therapy sessions. This model requires trained therapists, specialized treatment facilities, and extended session times, creating labor-intensive delivery costs estimated at $10,000 to $15,000 per patient for a complete treatment course.

Reimbursement remains uncertain. Medicare and private insurers have not established coverage policies for psychedelic-assisted therapy, and the high per-session cost may face resistance from payers accustomed to generic antidepressants costing pennies per dose. However, health economists have argued that psychedelic therapy could prove cost-effective if it produces durable remission, reducing long-term treatment costs and disability expenses. A 2022 analysis published in JAMA Psychiatry estimated that psilocybin therapy for treatment-resistant depression could be cost-effective at prices up to $17,500 per treatment course when accounting for quality-adjusted life years gained.

Intellectual property strategies focus on formulations, dosing regimens, and combination therapies rather than the psychedelic molecules themselves, most of which have been known for decades and cannot be patented. Compass Pathways holds patents on its crystalline psilocybin formulation and specific dosing protocols. MAPS has stated it will not seek composition-of-matter patents on MDMA but may pursue method-of-use patents covering its therapy protocol.

Regulatory certainty affects capital formation. Psychedelic biotechnology companies raised more than $1.8 billion between 2019 and 2021, but investment declined sharply in 2022 and 2023 as public market valuations fell and the FDA's complete response letter to MAPS raised concerns about approval timelines. Codifying research reforms into statute would provide investors with confidence that regulatory pathways will remain stable across presidential administrations, potentially reviving capital flows to the sector.

What Experts Say

Researchers have emphasized that legislative codification would provide the long-term stability necessary for multi-year clinical trials. According to statements from Johns Hopkins researchers, the current executive order represents significant progress, but future administrations could reverse it, creating uncertainty that discourages institutional investment in psychedelics research infrastructure. Permanent statutory authority would enable universities to commit resources to specialized facilities, training programs, and faculty positions with confidence that the regulatory environment will support their work.

Veterans advocacy organizations have supported the legislative effort. Iraq and Afghanistan Veterans of America stated in 2024 that psychedelic therapies represent a promising avenue for addressing the veteran mental health crisis and that federal policy should facilitate rather than obstruct research. The organization noted that many veterans have traveled to countries including Mexico, Costa Rica, and Jamaica to access psychedelic therapy in legal settings, highlighting unmet demand within the veteran community.

Drug policy reform advocates have cautioned that research reforms alone do not address broader questions of access and equity. The Drug Policy Alliance stated in response to the executive order that streamlined research is necessary but insufficient, and that federal policy should also address decriminalization of personal possession, expungement of prior convictions, and equitable access to approved therapies for marginalized communities disproportionately affected by both mental health conditions and drug war enforcement.

Law enforcement perspectives have evolved. The Major Cities Chiefs Association, representing police executives from the largest U.S. cities, stated in 2023 that psychedelics enforcement is not a priority for urban police departments facing violent crime and that resources are better allocated to addressing fentanyl trafficking and other acute public safety threats. Several police chiefs have endorsed deprioritization measures in their jurisdictions.

What's Next

The legislative timeline depends on committee assignments and broader congressional priorities, but Correa and Bergman indicated in May 2026 that they plan to introduce bill text before the August recess. The legislation would likely be referred to the House Energy and Commerce Committee, which has jurisdiction over FDA matters, and the House Judiciary Committee, which oversees DEA operations. Parallel Senate legislation would require a champion in that chamber; no senator has yet publicly committed to sponsoring companion legislation.

The FDA faces multiple psychedelic new drug applications in the near term. MAPS resubmitted its MDMA application with additional cardiovascular safety data in early 2026, and the agency is expected to issue a decision by late 2026 or early 2027. Compass Pathways anticipates completing its Phase 3 psilocybin trial in 2027, with a potential new drug application filing in 2028. Usona Institute has not announced a timeline for its psilocybin program following completion of Phase 2 trials.

State-level initiatives continue to advance. Ballot measures to establish psilocybin therapy programs are under consideration in Massachusetts and California for the November 2026 election. Legislative proposals to decriminalize possession or create regulated access frameworks have been introduced in New York, Connecticut, and Missouri. The outcomes of these state efforts will shape the political environment for federal reform.

International developments may influence U.S. policy. Australia reclassified psilocybin and MDMA as Schedule 8 controlled substances in February 2023, allowing authorized psychiatrists to prescribe them for treatment-resistant depression and PTSD, respectively—the first national regulatory approval for psychedelic therapy. Health Canada has granted exemptions under Section 56 of the Controlled Drugs and Substances Act to more than 30 healthcare professionals to use psilocybin in training and to more than 80 terminally ill patients to access psilocybin-assisted therapy. These international precedents provide real-world evidence that may inform FDA and DEA decision-making.

The DEA's five-factor analysis for rescheduling, required under 21 U.S.C. § 811(c), considers a substance's actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, and risk to public health. If FDA-approved psychedelic therapeutics enter the market, the DEA would face pressure to reschedule those specific formulations to Schedule II or III, enabling prescription under medical supervision while maintaining controls on diversion. Such rescheduling would require notice-and-comment rulemaking and could take two to three years to complete.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• FDA Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics (May 2014) — https://www.fda.gov/media/86377/download
• DEA Diversion Control Division, Controlled Substance Schedules — https://www.deadiversion.usdoj.gov/schedules/
• Oregon Psilocybin Services, Oregon Health Authority — https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx
• Johns Hopkins Center for Psychedelic and Consciousness Research — https://hopkinspsychedelic.org/
• Multidisciplinary Association for Psychedelic Studies (MAPS) — https://maps.org/
• Mitchell, J.M., et al. "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study." Nature Medicine 27 (2021): 1025-1033 — https://www.nature.com/articles/s41591-021-01336-3
• Goodwin, G.M., et al. "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression." New England Journal of Medicine 387 (2022): 1637-1648 — https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
• Congressional Psychedelics Advancing Therapies (PATH) Caucus — https://correa.house.gov/psychedelics-caucus
• National Institute on Drug Abuse, Research Resources Drug Supply Program — https://nida.nih.gov/research-topics/research-resources-drug-supply-program